𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Characterization of type I 5α-reductase activity in DU145 human prostatic adenocarcinoma cells

✍ Scribed by Kaefer, Martin; Audia, James E.; Bruchovsky, Nicholas; Goode, Robin L.; Hsiao, Kenneth C.; Leibovitch, Ilan Y.; Krushinski, Joseph H.; Lee, Chung; Steidle, Christopher P.; Sutkowski, Debra M.; Neubauer, Blake Lee

Book ID
122056184
Publisher
Elsevier Science
Year
1996
Tongue
English
Weight
926 KB
Volume
58
Category
Article
ISSN
0960-0760

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Responses of LNCaP prostatic adenocarcin
Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5α-reductase inhibitor
✍ Sutkowski, Debra M.; Audia, James E.; Goode, Robin L.; Hsiao, Kenneth C.; Leibov 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB 👁 1 views

We evaluated the metabolic inhibitory, antiproliferative, and antisecretory effects of LY300502, a benzoquinolinone human-specific type I-selective steroid 5a-reductase inhibitor in LNCaP human prostatic adenocarcinoma cell cultures. Reductive metabolism of [3H-T] in the LNCaP cells was inhibited in